Psoriasis laboratory findings

	Psoriasis Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Psoriasis from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
X-ray
Ultrasound
CT scan
MRI
Other Imaging Studies
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Psoriasis laboratory findings On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Psoriasis laboratory findings All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Psoriasis laboratory findings
CDC on Psoriasis laboratory findings
Psoriasis laboratory findings in the news
Blogs on Psoriasis laboratory findings
Directions to Hospitals Treating Psoriasis
Risk calculators and risk factors for Psoriasis laboratory findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Syed Hassan A. Kazmi BSc, MD [2]

Overview

Laboratory findings consistent with the diagnosis of psoriasis include increased levels of Long Pentraxin 3 protein (PTX3) and elevated complement levels.

Laboratory Findings

Enzyme linked immunosorbent assay (ELISA)

In patients with severe psoriasis, increased levels of Long Pentraxin 3 protein (PTX3) can be observed in plasma and in monocytic cultures by enzyme linked immunosorbent assay (ELISA).^[1]

Serum complement levels

The following abnormalities of serum complement levels may be observed in cases of psoriasis:^[2]

Increased serum IgA
Increased C3 in phalyngeal arthropathy associated with psoriasis
Increased C4
Increased C3PA concentrations
Increased CRP concentration in sacroiliitis associated with psoriasis

References

↑ Bevelacqua V, Libra M, Mazzarino MC, Gangemi P, Nicotra G, Curatolo S, Massimino D, Plumari A, Merito P, Valente G, Stivala F, La Greca S, Malaponte G (2006). "Long pentraxin 3: a marker of inflammation in untreated psoriatic patients". Int. J. Mol. Med. 18 (3): 415–23. PMID 16865225.
↑ Vinje O, Møller P, Mellbye OJ (1980). "Laboratory findings in patients with psoriasis, with special reference to immunological parameters, associations with arthropathy and sacro-iliitis". Scand. J. Rheumatol. 9 (2): 97–105. PMID 6159678.

Template:WH Template:WS

[pmid16865225-1] Bevelacqua V, Libra M, Mazzarino MC, Gangemi P, Nicotra G, Curatolo S, Massimino D, Plumari A, Merito P, Valente G, Stivala F, La Greca S, Malaponte G (2006). "Long pentraxin 3: a marker of inflammation in untreated psoriatic patients". Int. J. Mol. Med. 18 (3): 415–23. PMID 16865225.

[pmid6159678-2] Vinje O, Møller P, Mellbye OJ (1980). "Laboratory findings in patients with psoriasis, with special reference to immunological parameters, associations with arthropathy and sacro-iliitis". Scand. J. Rheumatol. 9 (2): 97–105. PMID 6159678.

[1]

[2]